https://orcid.org/0000-0002-9074-8770
References
- Sun JP. Written at the closing year of the “three 90%” strategic goal for AIDS prevention and treatment. Chin J Prev Med. 2020;54(11):1180–1183. doi:10.3760/cma.j.cn112150-20200915-01204
- Zeng YL, Tang HL, Li JM, et al. Survival analysis of people living with HIV/AIDS in Sichuan province, 1991–2017. Chin J Epidemiol. 2019;40(3):309–314. doi:10.3760/cma.j.issn.0254-6450.2019.03.010
- Zeng YL, Yu H, Yang W, et al. Assessment of effectiveness of antiretroviral therapy in HIV-positive adults in Sichuan Province from 2003–2019. J Prev Med Inf. 2022;38(5):587–593.
- Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441–446. doi:10.1086/510746
- Chen ZQ, Liang L, Li BJ, et al. Analysis for the correlation between CD4+ cell counts and opportunistic in patients with HIV/AIDS. Hebei Med J. 2009;31(19):2552–2553. doi:10.3969/j.issn.1002-7386.2009.19.013
- Zhangwen G, Feng Y, Kang L, et al. CRF01_AE and CRF01_AE cluster 4 are associated with poor immune recovery in Chinese patients under cART. Clin Infect Dis. 2020;8. doi:10.1093/cid/ciaa380
- Jiang H, Lan G, Zhu Q, et al. Impacts of HIV-1 subtype diversity on long-term clinical outcomes in antiretroviral therapy in Guangxi, China. JAIDS. 2022;89(5):583–591. doi:10.1097/QAI.0000000000002906
- Su L, Feng Y, Liang S, et al. The origin and spread of CRF85_BC, driven by heterosexual transmission among older people in Sichuan, China. BMC Infect Dis. 2020;20(1). doi:10.1186/s12879-020-05488-4
- Chinese center for disease control and prevention. A guideline for CR4+T lymphocyte counting and quality assurance in people living with HIV/AIDS; 2013.
- Chinese center for disease control and prevention. A guideline for HIV-1 viral load testing and quality assurance; 2013.
- Chinese center for disease control and prevention. Guideline for HIV-1 genotyping drug resistance testing and quality assurance; 2013.
- Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type I distinct from group M and group O. Nat Med. 1998;4(9):1032–1037. doi:10.1038/2017
- Chinese center for disease control and prevention. The Fourth Edition of the National Free AIDS Antiviral Treatment Handbook. Bei Jing: People’s Health Publishing House; 2016.
- General Office of the State Council. Action plan for containment and AIDS prevention in China in 13th five-year; 2017.
- Su L, Yang H, Hu Y, et al. Molecular epidemiological study on HIV-1 in Sichuan Province in 2014. Chin J Aids Std. 2016;22(12):946–949.
- Yuan D, Yu B, Liang S, et al. HIV-1 genetic transmission networks among people living with HIV/AIDS in Sichuan, China: a genomic and spatial epidemiological analysis. Lancet Reg Health West Pac. 2021;18:100318. doi:10.1016/j.lanwpc.2021.100318
- Gupta A, Wood R, Kaplan R, et al. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824. doi:10.1371/journal.pone.0055824
- Tran DA, Wilson DP, Shakeshaft A, et al. Determinants of virological failure after 1 year’s antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect. 2014;90(7):538–544. doi:10.1136/sextrans-2013-051353
- Lee MP, Zhou J, Messerschmidt L, et al. Impact of gender on long‐term treatment outcomes of highly active antiretroviral therapy (HAART) in the TREAT Asia HIV observational database. Aids Patient Care S Tds. 2015;29(5):229–231. doi:10.1089/apc.2014.0232
- National Development and Reform Commission (NDRC), People’s Republic of China. The 13th five-year plan for economic and social development of the people’s republic of China. Available from: https://en.ndrc.gov.cn/policyrelease_8233/201612/P020191101482242850325.pdf. Accessed March 16, 2016.
- Zhang YP. Influencing factors of stigma level in AIDS patients. Sichuan J Physiol Sci. 2021;43(3):419–422.
- Liang S, Yang H, Ye L, et al. Efficacy of extended treatment and influencing factors of HIV drug resistance patients in Sichuan. J Prev Med Inf. 2018;34(7):898–907.
- Yao SJ, Lv YN, Wang L, et al. The survival analysis in 7255 AIDS patients on antiretroviral therapy in Liaoning Province in 2003–2015. Chin J Dis Control Prev. 2016;20(12):1203–1207. doi:10.16462/j.cnki.zhjbkz.2016.12.005